Indefinite Delivery Contract 75N91023D00006
Award Date
4/11/23
Last Date to Order
4/10/28
Federal Agency
National Cancer Institute
Awardee
Alchem Laboratories Corporation
Ultimate Awardee
Not listed
NAICS Category
325412 - Pharmaceutical Preparation Manufacturing
PSC Category
B504 - Special Studies/Analysis- Chemical/Biological
Federal Contract Vehicle
Pricing Type
Order Dependent (IDV only)
Legislative Mandate
Employment Eligibility Verification
National Interest Action
None
Award Type
Single
Primary Consortia Member
Not listed
Similar IDVs
The National Cancer Institute, part of the National Institutes of Health within the Department of Health and Human Services, awarded a single award Indefinite Delivery Contract to Alchem Laboratories Corporation. The contract has a potential value of $7,777,665 and a period of performance from September 2017 to September 2022. Under the contract, Alchem Laboratories Corporation provides non-good manufacturing practices synthesis of small molecules to support the National Cancer Institute's...
The Department of Health and Human Services National Institutes of Health (NIH) awarded an Indefinite Delivery Contract (IDC) to Alchem Laboratories Corporation, doing business as Alchem Laboratories Corp, to provide drug formulation and manufacturing services. The $45,000,250 multiple-award IDC was partially set aside for small businesses and has a period of performance through September 2024. Under this IDC, Alchem Laboratories has been issued task orders to synthesize non-GMP small molecule...
This indefinite delivery contract (IDC) was awarded by the National Center for Advancing Translational Sciences (NCATS), a civilian agency within the U.S. Department of Health and Human Services, to Alchem Laboratories Corporation. The contract, valued at up to $17,891,012, is to provide CRO (contract research organization) support services for NCATS's Medicinal Chemistry for Lead Optimization program. Under this multiple-award IDC, Alchem Laboratories will perform a variety of preclinical and...
The federal contract IDV award is for Chemistry, Manufacturing, and Control (CMC) and related services to support the development of drug products for the National Center for Advancing Translational Sciences (NCATS), a civilian agency. This is a multiple award, indefinite delivery contract with a $49,885,703 ceiling value and a period of performance through July 2031. The prime contractor, Alchem Laboratories Corporation, is a for-profit pharmaceutical manufacturer that will provide a broad...
This indefinite delivery contract was awarded by the National Cancer Institute (NCI), part of the National Institutes of Health (NIH) under the Department of Health and Human Services (HHS). The contract, valued at up to $74,995,000, is a multiple award with Advanced Bioscience Laboratories, Inc. (ABL) as the prime contractor. The contract supports the PREVENT Cancer Preclinical Drug Development Program, with the objective of cGMP production of vaccines and biologicals for cancer prevention. Key...
This is an Indefinite Delivery Contract (IDC) awarded by the Department of Health and Human Services' National Institutes of Health (NIH) National Center for Advancing Translational Sciences (NCATS) to Advanced Bioscience Laboratories, Inc. (ABL) for Chemistry, Manufacturing and Controls (CMC) and related services to support the development of drug substances. The contract has a potential value of $49,713,679 and a period of performance from May 15, 2024 to May 14, 2031. It is a multiple award...
This single-award IDV was issued by the National Cancer Institute, part of the Department of Health and Human Services, on April 11, 2023 with a potential value of $12.1 million. The contract aims to procure analysis and synthesis of GMP and non-GMP bulk drugs and pharmaceutical formulations to support the Institute's research efforts. Research Triangle Institute was selected as the prime contractor to deliver the required products and services over a five-year ordering period ending April 10,...
This indefinite delivery contract (IDC) was awarded by the National Cancer Institute (NCI), a civilian agency, to Alliance For Advancing Biomedical Research, a non-profit organization, with a contract value ceiling of $89,000,000,000. The contract is for the management and operation of the National Cancer Institute's Federally Funded Research and Development Center (FFRDC)/Frederick National Laboratory for Cancer Research (FNLCR). The initial task order awarded under this IDC is a Firm Fixed...
The National Cancer Institute (NCI) awarded a multiple-award Indefinite Delivery Contract (IDC) with a $149,995,000 ceiling value to The Institute For Cancer Research, a non-profit organization and subsidiary of Temple University, to provide preclinical efficacy and biomarker analysis services in support of the PREVENT Cancer Preclinical Drug Development Program. This 5-year IDC contract includes three technical pools: Preclinical Efficacy and Biomarkers, Preclinical Services for Product...
This Indefinite Delivery Contract (IDC) was awarded by the National Center for Advancing Translational Sciences (NCATS), a civilian agency under the National Institutes of Health (NIH), to Advanced Bioscience Laboratories, Inc. (ABL). The $49.9 million, multiple-award IDC will provide Chemistry, Manufacturing, and Control (CMC) and related services to support the development of drug products from August 2024 through July 2031. The contract aims to obtain a broad range of preclinical services...